UB Paderborn / Katalog / Suche / in CDI

PEMFCs multiscale modeling: Determination of overpotential with description of electron transfer in cathodic EDL at different O2 concentrations

Electrochimica acta, 2020-01, Vol.331, p.135361, Article 135361

2020

Volltextzugriff (PDF)

Co-catalytic effect of nickel in Pt-Ru/C and Pt-Sn/C electrocatalysts for ethanol electrooxidation

Latin American applied research, 2010-04, Vol.40 (2), p.113-118

2010

Volltextzugriff (PDF)

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes

Drug metabolism and disposition, 2003-04, Vol.31 (4), p.421

2003

Volltextzugriff (PDF)

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Blood advances, 2024-04

2024

Volltextzugriff (PDF)

Nonspecific toxins as components of a host‐specific culture filtrate from Fusarium oxysporum f. sp. cubense race 1

Plant pathology, 2018-02, Vol.67 (2), p.467-476

2018

Volltextzugriff (PDF)

Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study

Blood, 2021-11, Vol.138 (Supplement 1), p.8-8

2021

Volltextzugriff (PDF)

FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease

Blood, 2020-11, Vol.136 (Supplement 1), p.19-20

2020

Volltextzugriff (PDF)

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Blood, 2019-11, Vol.134 (Supplement_1), p.3907-3907

2019

Volltextzugriff (PDF)

Development and SAR of functionally selective allosteric modulators of GABAA receptors

Bioorganic & medicinal chemistry, 2011-05, Vol.19 (9), p.2927-2938

2011

Volltextzugriff (PDF)

Quantitative Tissue Distribution and Pharmacokinetics of IW‐1973, a Novel Clinical‐Stage sGC Stimulator, After Oral Administration in Rats

The FASEB journal, 2017-04, Vol.31 (S1)

2017

Volltextzugriff (PDF)

B53 PHOUND IN TRANSLATION: Inhibition Of Fibrotic And Hypoxia Gene Response In A Pulmonary Vascular Surrogate System With A Small Molecule Stimulator Of Soluble Guanylate Cyclase

American journal of respiratory and critical care medicine, 2016-01, Vol.193, p.1

2016

Volltextzugriff (PDF)

Development and SAR of functionally selective allosteric modulators of GABA A receptors

Bioorganic & medicinal chemistry, 2011-05, Vol.19 (9), p.2927-2938

2011

Volltextzugriff (PDF)

Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: Lead optimization

Bioorganic & medicinal chemistry letters, 2003-12, Vol.13 (24), p.4299-4304

2003

Volltextzugriff (PDF)

Synthesis and structure–activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors

Bioorganic & medicinal chemistry letters, 2004-09, Vol.14 (17), p.4453-4459

2004

Volltextzugriff (PDF)

Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors

Journal of medicinal chemistry, 2001-10, Vol.44 (21), p.3347-3350

2001

Volltextzugriff (PDF)

Development and SAR of functionally selective allosteric modulators of GABA sub(A receptors)

Bioorganic & medicinal chemistry, 2011-05, Vol.19 (9), p.2927-2938

2011

Volltextzugriff (PDF)

Design and Synthesis of a Series of (2R)-N 4-Hydroxy-2-(3-hydroxybenzyl)-N - [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden- 1-yl]butanediamide Derivatives as Potent, Selective, and Orally Bioavailable Aggrecanase Inhibitors

Journal of medicinal chemistry, 2001-10, Vol.44 (21), p.3347-3350

2001

Volltextzugriff (PDF)

Design and Synthesis of a Series of (2R)-N4-Hydroxy-2-(3-hydroxybenzyl)-N- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden- 1-yl]butanediamide Derivatives as Potent, Selective, and Orally Bioavailable Aggrecanase Inhibitors

Journal of medicinal chemistry, 2001-10, Vol.44 (21), p.3347-3350

2001

Volltextzugriff (PDF)

Design and synthesis of a series of (2R)-N4-hydroxy-2-(3-hydroxybenzyl)-N1-[(1S, 2R)-2-hydroxy-2,3-dihydro-1H-inden-1 -yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors

Journal of medicinal chemistry, 2001, Vol.44 (21), p.3347-3350

2001

Volltextzugriff (PDF)

Resistance of the stromal cells in murine long-term bone marrow cultures to damage by ionizing radiation

Experimental hematology, 1986-12, Vol.14 (11), p.1056-1062

1986

Volltextzugriff (PDF)

Resistance of the stromal cell in murine long-term bone marrow cultures to damage by ionizing radiation

Experimental hematology, 1986-12, Vol.14 (11), p.1056

1986

Volltextzugriff (PDF)

Authors

Nuclear technology, 1971-07, Vol.11 (3), p.274-278

1971

Volltextzugriff (PDF)

Authors

Nuclear technology, 1971-07, Vol.11 (3), p.274-278

1971

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

PEMFCs multiscale modeling: Determination of overpotential with description of electron transfer in cathodic EDL at different O2 concentrations

Co-catalytic effect of nickel in Pt-Ru/C and Pt-Sn/C electrocatalysts for ethanol electrooxidation

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

Nonspecific toxins as components of a host‐specific culture filtrate from Fusarium oxysporum f. sp. cubense race 1

Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study

FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Demonstrates Proof of Mechanism and Proof of Concept after a Single Dose and after Multiple Daily Doses in a Phase 1 Study of Patients with Sickle Cell Disease

Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies

Development and SAR of functionally selective allosteric modulators of GABAA receptors

Quantitative Tissue Distribution and Pharmacokinetics of IW‐1973, a Novel Clinical‐Stage sGC Stimulator, After Oral Administration in Rats

B53 PHOUND IN TRANSLATION: Inhibition Of Fibrotic And Hypoxia Gene Response In A Pulmonary Vascular Surrogate System With A Small Molecule Stimulator Of Soluble Guanylate Cyclase

Development and SAR of functionally selective allosteric modulators of GABA A receptors

Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: Lead optimization

Synthesis and structure–activity relationship of a novel sulfone series of TNF-α converting enzyme inhibitors

Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors

Development and SAR of functionally selective allosteric modulators of GABA sub(A receptors)

Design and Synthesis of a Series of (2R)-N 4-Hydroxy-2-(3-hydroxybenzyl)-N - [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden- 1-yl]butanediamide Derivatives as Potent, Selective, and Orally Bioavailable Aggrecanase Inhibitors

Design and Synthesis of a Series of (2R)-N4-Hydroxy-2-(3-hydroxybenzyl)-N- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden- 1-yl]butanediamide Derivatives as Potent, Selective, and Orally Bioavailable Aggrecanase Inhibitors

Design and synthesis of a series of (2R)-N4-hydroxy-2-(3-hydroxybenzyl)-N1-[(1S, 2R)-2-hydroxy-2,3-dihydro-1H-inden-1 -yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors

Resistance of the stromal cells in murine long-term bone marrow cultures to damage by ionizing radiation

Resistance of the stromal cell in murine long-term bone marrow cultures to damage by ionizing radiation

Authors

Authors

Suchergebnisse filtern